Tech Company Financing Transactions
Qi Biodesign Funding Round
Qi Biodesign, based in Suzhou, Jiangsu, secured $75 million from Beijing Medical and Health Care Industry Investment Fund, Beijing Changping Technology Innodevelop Group and CD Capital.
Transaction Overview
Company Name
Announced On
12/6/2024
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Proceeds Purpose
The newly secured funding will be used to enhance Qi Biodesign's R&D capabilities, advance its proprietary SEEDIT� platform, support its product development and build commercialization platforms to streamline and speed up the transition from research to market.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Suzhou Industrial Park, Unit E598, 5th Floor, Lecheng Plaza,
Suzhou, Jiangsu, 215000
China
Suzhou, Jiangsu, 215000
China
Phone
Website
Email Address
Overview
Global Leading Genome Editing Technologies; Driving Innovations in Plant Breeding. Mission: Biodesigning for a better future. Vision: Global leading Biotechnology company; Developing novel precision genome editing technologies; Developing elite traits & innovative products.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bei Zhang
Chief Technical Officer
Kevin Zhao
Co-Founder
Caixia Gao
VP - Bus. Development
Haiquan Yang
Browse more venture capital transactions:
Prev: 12/6/2024: Much Better Adventures venture capital transaction
Next: 12/6/2024: Realta Fusion venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs